# Andrew Levin

> Andrew Levin is a Series A investor at RA Capital Management backing Biotechnology. See 24 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management)
- Location: Boston, United States
- Total investments: 24
- Last investment: Feb 2026
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/andrew-levin-1481783

Andrew Levin is a Series A investor at RA Capital Management in Boston focused on Biotechnology and Health Care. Andrew Levin is based out of Boston, Massachusetts and is the Board Member of Pahr Therapeutics and Managing Director of RA Capital Management. Andrew previously worked at H.I.G. Capital as a Vice President. Andrew Levin attended Harvard Medical School.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 13 | 54% |
| Health Care | 5 | 21% |
| Therapeutics | 5 | 21% |
| Pharmaceutical | 5 | 21% |
| Medical | 3 | 13% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 9 | 38% |
| Series B | 7 | 29% |
| Seed | 2 | 8% |
| Series C | 2 | 8% |
| Post-IPO Equity | 1 | 4% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 12 | 50% |
| United Kingdom | 1 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Slate Medicines | Slate Medicines is a biotechnology company that develops therapeutics that target Pituitary Adenylate Cyclase-Activating Polypeptide for migraine treatment and prevention. The company aims to revolutionize migraine prevention for patients seeking alternative solutions. | $130M | Series A | Feb 24, 2026 |  |
| Imbria Pharmaceuticals | Imbria Pharmaceuticals’ mission is to translate our understanding of cellular metabolism into innovative medicines that improve the lives of patients with limited or inadequate treatment options. The company was founded by doctors and launched by an all doctor executive team motivated by the promise of bringing new therapies to people in need. Weare propelled by a deep scientific interest in cellular metabolism and the mitochondria, and are guided by both values and a code of business conduct built upon our commitment to always put the patients, families and communities we serve at the forefront of all that we do. |  | Series B | Nov 17, 2025 |  |
| Alchemab Therapeutics | Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases. | $32M | Series A | Sep 09, 2025 |  |
| Pahr Therapeutics | Pahr Therapeutics is a clinical-stage business whose goal is to create innovative ways to treat pulmonary arterial hypertension. | $14M | Seed | Jul 28, 2025 |  |
| Imbria Pharmaceuticals | Imbria Pharmaceuticals’ mission is to translate our understanding of cellular metabolism into innovative medicines that improve the lives of patients with limited or inadequate treatment options. The company was founded by doctors and launched by an all doctor executive team motivated by the promise of bringing new therapies to people in need. Weare propelled by a deep scientific interest in cellular metabolism and the mitochondria, and are guided by both values and a code of business conduct built upon our commitment to always put the patients, families and communities we serve at the forefront of all that we do. | $66.7M | Series B | Apr 10, 2025 |  |
| Aktis Oncology | Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy.Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. | $175M | Series B | Sep 30, 2024 |  |
| Superluminal Medicines | Superluminal Medicines is a generative biological and chemical company accelerating new possibilities in drug discovery and development. Its platform creates candidate-ready compounds with speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. | $120M | Series A | Sep 09, 2024 |  |
| Navigator Medicines | Navigator Medicines operate as a biotech company that leads the advancement of biologics for targeted immune regulation & restoration. | $100M | Series A | Aug 27, 2024 |  |
| Climb Bio | Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders. The company leverages its expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline.Eliem Therapeutics develops and commercializes potentially“best-in-class” drug candidates to treat neuronal excitability disorders. These conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. | $120M | Post-IPO Equity | Apr 11, 2024 |  |
| Superluminal Medicines | Superluminal Medicines is a generative biological and chemical company accelerating new possibilities in drug discovery and development. Its platform creates candidate-ready compounds with speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. | $33M | Seed | Aug 28, 2023 |  |

10 of 24 investments shown.

## Co-investors
- [Deep Track Capital](https://shizune.co/investors/profile/deep-track-capital) — VC Fund, 5 deals together
- [5AM Ventures](https://shizune.co/investors/profile/5am-ventures) — VC Fund, 4 deals together
- [SV Health Investors](https://shizune.co/investors/profile/sv-life-sciences) — VC Fund, 4 deals together
- [AN Ventures](https://shizune.co/investors/profile/an-ventures) — VC Fund, 3 deals together
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 3 deals together
- [Eli Lilly](https://shizune.co/investors/profile/eli-lilly) — VC Fund, 3 deals together

## About RA Capital Management

VC Fund · Boston, United States

RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.

5 contacts available at RA Capital Management.

| Name | Title | Profile |
| --- | --- | --- |
| Cristina Ghenoiu | Principal | https://shizune.co/investors/profile/cristina-ghenoiu |
| Ajay Yekkirala | VP, Head of Biology | https://shizune.co/investors/profile/ajay-yekkirala-9184 |
| Andrew Levin | Managing Director | https://shizune.co/investors/profile/andrew-levin |
| Barbara Herbst | Deputy Chief Compliance Officer | https://shizune.co/investors/profile/barbara-herbst |
| Dan Marks | Venture Senior Associate | https://shizune.co/investors/profile/dan-marks |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Andrew Levin invest in?

Andrew Levin invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Andrew Levin last invest?

The most recent investment recorded for Andrew Levin closed in Feb 2026. Shizune tracks 24 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co